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Summary: 
 
      Pre-hematopoietic stem cell transplantation (HSCT) dental treatment is essential 
to prevent serious infections from oral sources during immunosuppression in patients 
who undergo HSCT therapy. This study was planned to establish a dental 
management protocol for these patients. Forty-one patients scheduled for HSCT to 
treat hematological malignancies were consecutively enrolled in the prospective trial. 
The dental status of all the patients was evaluated by clinical and radiographic 
examination at a median of 47 days before the commencement of HSCT therapy. 
Thirty-six patients had one or more dental diseases; the remaining 5 had none. Caries 
was found in 26 patients, apical periodontitis in 19, marginal periodontitis in 24, and 
partially erupted third molar in 11. Our policy is to preserve patients’ teeth whenever 
possible, and therefore minimal dental intervention was planned. Treatment was 
completed for all 36 patients with dental pathologies, before the conditioning regimen 
began. All the patients received the scheduled HSCT therapy without alteration, 
interruption, or delay, and did not show any signs or symptoms associated with 
odontogenic infection while they were immunosuppressed. This protocol, therefore, 
appears to be appropriate for the pre-HSCT dental treatment of patients with 
hematological diseases. 
 
Keywords: Dental management; Hematopoietic stem cell transplantation (HSCT); 
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Introduction  
 
Hematopoietic stem cell transplantation (HSCT) has become an essential 
treatment for many patients with malignant and nonmalignant hematological diseases, 
including acute and chronic leukemias, aplastic anemia, myelodysplastic syndromes, 
and lymphomas 1, 2. Although HSCT is an effective treatment modality for these 
patients, successful engraftment after HSCT requires adequate immunosuppression of 
the recipient, which is accomplished with total body irradiation, chemotherapy, or a 
combination of both. Their immunosuppressed status makes the patients more 
susceptible to infection, resulting in an increased risk of infectious complications, 
including the development of severe septicemia, that may be life-threatening 2, 3.  
The oral cavity is a potential site of such infectious complications in patients 
receiving HSCT therapy, because it is an important port of entry for agents that can 
cause systemic infections 4-7. To prevent these oral complications, pre-transplant 
comprehensive oral care has been incorporated into the preparatory steps for patients 
scheduled to receive HSCT therapy. This approach is supported by the National 
Institutes of Health consensus statement on oral complications of cancer therapy 
(1989), which states, “dental foci are potential sources of systemic infections that 
need to be eliminated or ameliorated before commencement of anticancer therapy.” 8 
Therefore, to prevent significant morbidity, all sources of potential infection should be 
identified upon pre-transplant dental screening and treated appropriately2,9,10.  
Not all previous studies have supported a need for pre-HSCT dental treatment. 
Melkos et al 11 reported there was no significant difference in the occurrence of 
infection originating from oral disease during and after HSCT therapy between 
patients with and without pre-HSCT dental treatments, but they did not describe in 
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detail the severity of the dental diseases of the patients in their study. Tolijanic et al 12 
demonstrated that oncologic treatment outcomes were unaffected by the presence of 
chronic dental disease or acute exacerbations of these disease states in a pilot study in 
which no chronic dental diseases were treated regardless of severity, but the great 
majority of the patients in their study received only chemotherapy, which does not 
require the serious immunosuppression needed for HSCT therapy. Given the 
limitations of these studies, pre-HCST dental therapy is still indicated to prevent 
odontogenic complications. 
The potentially complicating oral conditions that have been identified are: dental 
caries, pulpitis, apical and marginal periodontitis, and partially erupted third molar. 
Dental care for these disorders includes tooth brushing instruction, scaling, restoration, 
pulpectomy, and endodontic treatment. Tooth extraction is recommended for severe 
dental disease. Such pre-HSCT dental treatments are anticipated to decrease the risk 
of local and systemic odontogenic infections during patient immunosuppression.  
Considering the limited period available for pre-HSCT dental treatment 13, 
minimal dental intervention to treat only the sources of potential infection is 
recommended. However, treatment protocols that clearly define the best treatment 
modality for patients at their pre-HSCT dental assessment are needed. We previously 
used retrospective data to construct a brief dental management protocol for patients 
scheduled to undergo HSCT therapy for hematologic diseases and evaluated its 
usefulness 14. However, a protocol defining the appropriate detailed treatment 
modality according to the severity of each dental disorder remains to be described. 
This study was prospectively carried out to establish detailed treatment criteria for 
minimal intervention in potentially detrimental dental disorders and to judge the 
effectiveness of the protocol.        
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Patients and methods 
 
Seventy-one candidates for HSCT therapy were referred from the Division of 
Hematology, Tsukuba University Hospital to the Division of Oral and Maxillofacial 
Surgery, which is the same hospital that carried out the screening of dental pathology 
between 1998 to 2004. Of 71 patients with hematological malignancies, 41 underwent 
HSCT therapy; 30 did not because their general condition was poor or because no 
appropriate donor could be found. The 41 patients were consecutively enrolled into 
the prospective trial.  The subjects were 22 males and 19 females, ranging in age from 
17 to 58 years with a mean of 41.3 years. All participants gave informed consent prior 
to proceeding with treatment. The hematologic diagnoses were as follows: 14 patients 
had chronic myeloid leukemia, 7 had malignant lymphoma, 4 had acute myeloid 
leukemia, 4 had non-Hodgkin lymphoma, 4 had myelodysplastic syndrome, 3 had 
multiple myeloma, 3 had acute lymphoid leukemia, and 2 had other malignancies. 
Hematopoietic stem cells were collected from the bone marrow of 28 patients and 
from the peripheral blood of 13 (Table 1).  
The dental status of all the patients was evaluated at the initial visit before HSCT 
by one experienced dentist. The screening examination consisted of a clinical 
examination of the hard and soft oral tissues and a radiographic survey, including 
panoramic and occasional periapical films for symptomatic teeth. All dental diseases 
encountered, including caries, apical periodontitis, marginal periodontitis, and 
impacted third molar, were recorded for each patient. Dental foci were defined as 
caries, apical and marginal periodontitis, and partially erupted third molar.  
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A new protocol was designed to preserve diseased teeth whenever possible, 
compared with the previous protocol14 (see Figure 1). This protocol defines the pre-
HSCT dental treatment modality for the dental foci identified, taking into account a 
patient’s status and treatment schedule. We describe the details of the protocol below: 
 
Teeth with mild or moderate caries are restored in patients with sufficient time 
for dental treatment, but observed in those without enough time. Decayed teeth with 
pulpitis are treated by pulpectomy and root canal filling. The residual roots are 
extracted.  
Teeth with recently symptomatic apical periodontitis or asymptomatic apical 
periodontitis and periapical radiolucency of the maximal diameter greater than 5 mm 
are treated with root canal in patients whose schedule permits, but the teeth are 
removed if there isn’t enough time for treatment. Asymptomatic apical periodontitis 
with periapical radiolucency of less than 5 mm is not treated. 
 Marginal periodontitis, teeth with gingival swelling, pain and purulent discharge, 
a probing depth greater than 8 mm, or severe mobility are removed, whereas teeth 
with marginal periodontitis but without these signs and symptoms are observed and 
tooth brushing instruction and/or scaling is provided.  
Partially erupted third molars affected with pericoronitis or purulent drainage are 
extracted, and asymptomatic third molars are not treated.  
All patients, including those without dental foci, are given tooth brushing 
instructions to exfoliate dental plaque. 
 
For the HSCT procedure, all patients were admitted to a disinfected room. 
During the conditioning period, each patient experienced at least one episode of a 
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temperature higher than 38 degrees C and an absolute white blood cell count 
(WBC) of less than 1,000/ml lasting more than several days, as manifestations of 
their immunosuppressed status. The dental follow-up was conducted during the 
only HSCT hospitalization, which was approximately 3 weeks long. Any patient 
with local signs and symptoms consistent with odontogenic infections, such as 
swelling, pain, redness, and sensitivity of the gingiva surrounding the teeth had a 
dental consultation and was given treatment as necessary. The frequency and 
occurrence of oral complaints and complications were recorded on the patients’ 
medical charts and investigated throughout the course of HSCT therapy, and the 
effectiveness of the new detailed protocol was assessed by the attending dentists 
and hematologists.  
 
Results 
 
The dental status of all the patients was evaluated between 7 and 240 days before 
the commencement of HSCT therapy, with a median of 47 days. Dental treatment 
must be complete 10 days before HSCT therapy, to give the patient time to undergo 
the conditioning regimen for HSCT. The time available for dental treatment was less 
than 1 month for 13 patients, from 1 to 2 months for 11, from 2 to 3 months for 7, and 
more than 3 months for 10. The patients with duration of more than 2 months between 
dental examination and the commencement of HSCT therapy were re-examined to 
check new dental disease within 1 month before HSCT therapy. Thirty-eight of the 41 
patients (92.7%) had one or more dental diseases. Caries was discovered in 101 teeth 
in 26 patients, pulpitis in 5 teeth in 2 patients, apical periodontitis in 43 teeth in 19 
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patients, marginal periodontitis in 94 teeth in 24 patients, and partially erupted third 
molar in 21 teeth in 11 patients (Table 2). Three patients had no dental disease.  
Using the new protocol, 36 patients received one or more kinds of dental 
treatment. Of 101 caries in 26 patients, 40 cases in 12 patients were restored, and the 
remaining 61 teeth of 14 patients were not treated. All five cases of pulpitis were 
treated with pulpectomy and root canal filling. Of 43 teeth with apical periodontitis in 
19 patients, 41 were asymptomatic and 2 were symptomatic. Periapical lesions greater 
than 5 mm were observed in 10 teeth in 8 patients and lesions smaller than 5 mm in 
33 teeth in 11. Seven teeth with asymptomatic lesions greater than 5 mm in 7 patients 
were removed, 5 teeth in 4 patients, including 2 that were symptomatic and 3 that 
were asymptomatic, that had a lesion of over 5 mm were treated endodontically, and 
the remaining 31 teeth in 13 patients with asymptomatic apical periodontitis and 
periapical lesions of less than 5 mm were followed without treatment. Of 94 teeth 
affected with marginal periodontitis, 6 teeth of 5 patients were removed, and the 
remaining 88 teeth of 24 patients were preserved with scaling and professional tooth 
brushing instruction. Only 3 of 21 partially erupted third molars were symptomatic. 
One patient had 2 symptomatic lower third molars. All 3 symptomatic teeth were 
extracted, and 8 upper and 10 lower asymptomatic third molars were not treated 
(Table 3). The planned dental treatment was completed for 36 patients before the 
initiation of the conditioning regimen. There was no new dental pathology at re-
examination. All 41 patients, including the 5 that did not require dental treatment, 
underwent HSCT therapy without showing signs or symptoms associated with 
odontogenic infection.  
The median number of days in which patients’ temperature was higher than 38 
degrees C during HSCT was 4, ranging from 0 to 60 days, with no significant 
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difference between bone marrow transplantation (BMT) and peripheral blood stem 
cell transplantation (PBSCT). The median number of days which the patients had a 
WBC of less than 1,000/ml was 17 ranging from 6 to 75 days for BMT, and 10 
ranging from 0 to 12 days for PBSCT. There was a statistical difference in the number 
of days of WBC less than 1,000/ml between the two HSCT modalities.  
Only two of the 41 patients (4.9%) experienced gingival pain before and during 
HSCT therapy. One was a 31-year-old female who complained of mild pain at the 
lower anterior gingiva, where gingivitis had been induced by anti-cancer agents. 
Another was a 30-year-old male who complained of mild pain at the gingiva of the 
upper third molar, which was under observation as asymptomatic. In both cases, there 
were no symptoms except pain, and there was no possibility of odontogenic infection. 
The pain of both patients resolved spontaneously, without treatment, and the 
scheduled HSCT therapy could continue. Thus, no alteration, interruption, or delay of 
HSCT therapy was required for any patient.   
 
Discussion 
 
Pre-HSCT dental screening to identify and treat potential oral sources of 
infection has become standard care in patients scheduled for HSCT therapy 3, 7. The 
principal aim of the screening is to reduce morbidity and mortality that may arise 
from oral complications associated with HSCT therapy during immunosuppression. 
Although all potential sources of oral infection should be eliminated by dental 
treatment before the initiation of the conditioning regimen, time limitations and the 
severity of a patient’s disease status frequently interfere with complete treatment 3, 6, 7, 
13. Given this restriction, the removal of potentially preservable diseased teeth may be 
 10
the only viable treatment option available, resulting in oral care that does not best 
serve the long-term oral needs of the patients, because the removal of multiple teeth 
may compromise nutrition during and after HSCT therapy 15. As a further 
complication of extraction, there is an associated increased risk of infection, bleeding, 
or delayed wound healing that could require postponing the scheduled HSCT therapy 
16-18.    
A comparison between patients with no dental foci or completed dental 
treatment and those with dental foci or no dental interventions demonstrated that the 
impact of dental foci on the occurrence of post-HSCT infections was not statistically 
significant 11. Patients with chronic dental pathology were reported to be safe in 
proceeding with chemotherapy without dental intervention, as the conversion of 
chronic dental disease to an acute state during chemotherapy occurs infrequently 12. 
These reports suggest that intensive pre-HSCT dental treatment is not necessary. 
Furthermore, patients should avoid the additional morbidity or mortality associated 
with needless treatment. Consequently, minimal dental intervention is recommended.  
Our previous dental management protocol was evaluated as significantly 
beneficial as a pre-HSCT dental treatment for patients scheduled to undergo HSCT 
therapy, but included removing potentially salvageable teeth to prevent the occurrence 
of infection during the therapy 14. From our experience and the desire to preserve teeth 
if possible, we designed a new protocol for minimal intervention, in which the 
treatment modality is decided according to the severity of the disease, and only 
severely diseased teeth are extracted. The time available to treat dental disorders in 
the current study was longer than in other reports 13, resulting in the completion of the 
planned dental treatments prior to the conditioning regimen in all patients. It is 
important that the planned treatment be completed before HSCT therapy, even if 
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minimal dental intervention is adopted, so early dental screening and treatment is 
essential. However the patients with duration of more than 2 months between the 
dental examination and the commencement of HSCT therapy had the possibility of 
arising new dental disease after dental examination. Therefore, we considered that the 
re-examination should be carried out in order not to miss new dental disease within 1 
month before HSCT therapy. 
 Most studies and the current protocol agree about the treatment modality for 
caries, symptomatic periapical lesion, severe advanced marginal periodontitis, and 
symptomatic partially erupted third molar 3, 7, 17, 19, 20. However, considerable 
controversy remains as to the best treatment for asymptomatic periapical lesion, 
chronic marginal periodontitis, and asymptomatic partially erupted third molar, and 
different dentists manage these pathologies with approaches that vary from very 
conservative to aggressive.  
As regards asymptomatic apical periodontitis, one study suggests that there is 
no increase in the incidence of infectious complications during HSCT therapy when 
teeth with post-endodontic periapical radiolucencies of greater than 1.5 mm are not 
treated19. Our previous study also showed that untreated periapical radiolucencies 
smaller than 2 mm did not convert to the acute stage during HSCT therapy 14. 
However, treatment is commonly required for large periapical lesions in the healthy 
population. In the present study, we did not treat asymptomatic periapical 
periodontitis with apical radiolucencies that were smaller than 5 mm, and there was 
no occurrence of conversion to the acute stage or of infectious complications. The 
patient outcomes of the present study suggest that it is safe not to treat asymptomatic 
apical lesions smaller than 5 mm before immunosuppressive conditioning.  
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Chronic marginal periodontitis is the most common significant dental infection 
that affects HSCT patients 4, 6, 21. A retrospective investigation reported that 64% of 
patients with chronic periodontal diseases had positive blood cultures associated with 
clinical signs of septicemia during the initial 100 days after HSCT15. However, 
because little data are available about the effect of pre-HSCT dental treatment for 
chronic periodontitis on the incidence of infectious complications, the treatment 
modality has varied from observing the affected teeth to removing asymptomatic teeth 
22-24. Teeth with a poor periodontal prognosis are generally extracted, but no 
relationship has been found between radiographic periodontal status and the incidence 
of septicemia 15. In the present protocol, only symptomatic teeth with acute 
conversion, a probing depth greater than 8 mm, or severe mobility were extracted; 
teeth without these symptoms were treated with scaling, and the patient was instructed 
in proper brushing technique. There was no occurrence of infectious complications in 
these patients. These outcomes indicate that teeth with chronic marginal periodontitis, 
except for actively infectious teeth, can be treated conservatively.  
There are two basic treatment options for managing an impacted, asymptomatic 
third molar. Some advocate prophylactic extraction as soon as possible 22, 25, whereas 
others prefer a more conservative approach 17, 26, because the risk of developing 
diseases associated with the third molar may be further reduced if the patient has good 
oral hygiene. In one study, 40% of patients who underwent the prophylactic removal 
of partially erupted or impacted third molars, which were symptomatic or 
asymptomatic, experienced postoperative complications, such as bleeding, alveolitis, 
trismus, or infection, in the course of intensive cancer therapy, including BMT 17. The 
complication rate among these patients was much higher than that reported in healthy 
population 27. In that report, the symptoms of most non-extracted symptomatic third 
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molars were treated with antibiotics and analgesics, but the impact on the outcomes of 
the scheduled HSCT therapy was not described. In the current protocol, symptomatic 
third molars were removed, and asymptomatic third molars were untreated, and there 
was no occurrence of odontogenic infection 17. The outcomes obtained using this 
management approach indicate that extraction for symptomatic third molars and non-
intervention for asymptomatic ones is a safe treatment.  
After completing the dental treatments, which followed the newly designed 
protocol, all the patients received their scheduled HSCT therapy without alteration, 
interruption, or delay, and they did not experience signs or symptoms associated with 
odontogenic infection during the immunosuppressive stages. Consequently, the new 
protocol is likely to be appropriate for guiding the pre-HSCT dental treatment of 
patients with hematological diseases.  
Some studies report that systemic oral assessment, regular encouragement of 
patient self-care, and consistent oral care may be the most important factors related to 
the prevention or amelioration of oral infection during HSCT therapy 7, 21, 28. In 
addition to the management of oral diseases, patient caregivers should provide careful 
instructions in advance about oral care during the immunosuppressive stages. Before 
dental treatment, all patients in the present study were educated to exfoliate dental 
plaque, which produces dental caries and marginal periodontitis. The extent to which 
the dental instruction influenced the absence of oral infection in the present study is 
unknown, but we believe the instruction was beneficial. Further studies with a larger 
sample size are required to confirm the appropriateness of the newly designed dental 
treatment protocol.   
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Table 1   Oncologic diagnosis and medical treatment 
 
Disease                                No. of patients    
 
Chronic myeloid leukemia (CML)                                  14 
 
Malignant lymphoma (ML)                                               7 
 
Acute myeloid leukemia (AML)                                       4 
 
Non-Hodgkin’s lymphoma (NHL)                                4 
 
Myelodysplastic syndrome (MDS)                                         4 
 
Multiple myeloma (MM)                                                        3 
 
Acute lymphoid leukemia (ALL)                                            3 
 
Others                                                                                2 
                                                                
 
Medical treatment                                                      No. of patients 
 
Bone marrow transplant (BMT)                                          28 
 
Peripheral blood stem cell transplant (PBSCT)                  13  
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Table 2 Dental diseases 
 
Dental Disease                       No. of patients                  No. of teeth 
 
Caries                                                  26                          101 
 
Pulpitis                                                  2                               5 
  
Apical periodontitis                         19                                      43 
 
Marginal periodontitis                         24                                     94 
 
Partially erupted third molar               11                                      21 
 
 
* More than one odontogenic disorder was diagnosed in some patients.  
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Table 3   Dental treatment outcome 
 
Dental treatment                                      No. of patients            No. of teeth 
 
Restoration                                               12                              40 
 
Scaling                                                               24 
 
Professional tooth brushing instruction             21 
 
Extraction                                                           10                             14 
        Apical periodontitis                                      7                               7 
        Marginal periodontitis                                  5                               6 
        Partially erupted third molar                        2                                3 
 
Pulpectomy                                                           2                               5 
 
Endodontic treatment                                           4                                5 
 
 
 
Present protocol                                                 Previous protocol 14
Caries                  Caries 
                                                                                                                                                    
Apical Periodontitis                                                 Apical Periodontitis   
 
                                      
Symptom
Periapical 
radiolucency
(diameter) 
Extraction 
No treatment 
Present Absent 
≥2mm < 2mm
Treatment
Symptom 
Periapical 
radiolucency 
(diameter) 
Extraction 
No treatment
Present Absent 
≥5mm < 5mm 
Root canal 
treatment Treatment 
 
Marginal Periodontitis            Marginal Periodontitis      
  
  Extraction 
Teeth brushing instruction 
or Scaling 
Mild to moderate Severe 
Treatment
Severity
 
 
 
 
Partially erupted third molar           Partially erupted third molar             
   
Symptom Present Absent
Extraction No treatment Treatmen
 
                                            
Figure 1  Dental treatment Protocol for HSCT candidates  
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